United States Federal Circuit

ResetAA Font size: Print

Phigenix, Inc. v. Immunogen, Inc., 2016-1544

In an appeal of the inter partes review decision of the Patent Trial and Appeal Board (PTAB) finding certain claims of a patent that relates to 'huMab4D5 ANTI-ErbB2 antibody-maytansinoid conjugates' as nonobvious, the matter is dismissed where plaintiff has not offered sufficient proof establishing that it has suffered an injury in fact, and thus, it lacks standing to bring suit in federal court.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/01/09




  • United States Federal Circuit


FindLaw Career Center

      Post a Job  |  View More Jobs

    View More